Fletikumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameFletikumab
Drug Alias Namefletikumabum夫来库单抗伏替介人单抗Anti-IL-20NNC-01090012 +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin 20 inhibitors
TargetsInterleukin 20
Therapy Area/IndicationsInflammationPsoriasisArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[18] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesZymogenetics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNovo Nordisk A/S
Active IndicationsN/A
Inactive IndicationsInflammationPsoriasisArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksWikipedia